Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)

NCT02716766 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Hepatocellular
Secondary

Interventions

DRUG: Sorafenib
DRUG: Capecitabine
DRUG: Oxaliplatin

Sponsor

The University of Hong Kong